PDF(1689 KB)
Research advances in treatment of cervical dystonia
Zihao ZHUANG, Jiacheng ZHANG, Kaihan SU, Qingbo LÜ, Huanan LI, Jingui WANG
Journal of Neurology and Neurorehabilitation ›› 2026, Vol. 22 ›› Issue (2) : 157-167.
PDF(1689 KB)
PDF(1689 KB)
Research advances in treatment of cervical dystonia
Cervical dystonia (CD) is the most common type of adult-onset focal dystonia, which can significantly impair patients' self-care ability and quality of life. Current mainstream therapeutic approaches include botulinum toxin therapy, pharmacotherapy, surgical treatment, physical therapy, psychological therapy, and characteristic therapies of traditional Chinese medicine (TCM). This paper conducts a literature review on the existing therapeutic modalities for CD and summarizes the efficacy, safety and limitations of different interventional measures. It is found that the existing therapies exert definite effects in managing the motor symptoms of CD, whereas obvious deficiencies remain in the efficacy evaluation and clinical attention to non-motor symptoms such as depression and anxiety. Future research should focus on exploring multimodal individualized treatment regimens integrating pharmacotherapy, surgery, rehabilitation and psychological intervention, so as to achieve precise matching of patients' treatment needs and comprehensive improvement of their quality of life.
Cervical dystonia / Botulinum toxin / Deep brain stimulation / Physiotherapy
| [1] | ALBANESE A, BHATIA K, BRESSMAN S B, et al. Phenomenology and classification of dystonia: A consensus update[J]. Mov Disord, 2013, 28(7):863-873. |
| [2] | LAHUE S C, ALBERS K, GOLDMAN S, et al. Cervical dystonia incidence and diagnostic delay in a multiethnic population[J]. Mov Disord, 2020, 35(3):450-456. |
| [3] | STEEVES T D, DAY L, DYKEMAN J, et al. The prevalence of primary dystonia: A systematic review and meta-analysis[J]. Mov Disord, 2012, 27(14):1789-1796. |
| [4] | ALBANESE A, BHATIA K P, CARDOSO F, et al. Isolated cervical dystonia: Diagnosis and classification[J]. Mov Disord, 2023, 38(8):1367-1378. |
| [5] | JUNKER J, HALL J, BERMAN B D, et al. Longitudinal predictors of health-related quality of life in isolated dystonia[J]. J Neurol, 2024, 271(2):852-863. |
| [6] | MOLHO E S, STACY M, GILLARD P, et al. Impact of cervical dystonia on work productivity: An analysis from a patient registry[J]. Mov Disord Clin Pract, 2016, 3(2):130-138. |
| [7] | DRESSLER D, ADIB SABERI F, ROSALES R L. Botulinum toxin therapy of dystonia[J]. J Neural Transm, 2021, 128(4):531-537. |
| [8] | SIMPSON D M, HALLETT M, ASHMAN E J, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache [RETIRED]: Report of the Guideline Development Subcommittee of the American Academy of Neurology[J]. Neurology, 2016, 86(19):1818-1826. |
| [9] | RODRIGUES F B, DUARTE G S, MARQUES R E, et al. Botulinum toxin type A therapy for cervical dystonia[J/OL]. Cochrane Database Syst Rev, 2020, 11(11):CD003633[2025-12-31]. . |
| [10] | MARQUES R E, DUARTE G S, RODRIGUES F B, et al. Botulinum toxin type B for cervical dystonia[J/OL]. Cochrane Database Syst Rev, 2016, 2016(5):CD004315[2025-12-31]. . |
| [11] | DUDZIC M, PIECZY?SKA A, DRU?D? A, et al. Does botulinum toxin type A treatment influence non-motor symptoms in cervical dystonia patients? A systematic review[J]. Neurol Neurochir Pol, 2025, 59(2):144-152. |
| [12] | JINNAH H A, COMELLA C L, PERLMUTTER J, et al. Longitudinal studies of botulinum toxin in cervical dystonia: Why do patients discontinue therapy?[J]. Toxicon, 2018, 147:89-95. |
| [13] | FERREIRA J J, COLOSIMO C, BHIDAYASIRI R, et al. Factors influencing secondary non-response to botulinum toxin type A injections in cervical dystonia[J]. Parkinsonism Relat Disord, 2015, 21(2):111-115. |
| [14] | ERRO R, PICILLO M, PELLECCHIA M T, et al. Improving the efficacy of botulinum toxin for cervical dystonia: A scoping review[J]. Toxins, 2023, 15(6):391[2025-12-31]. . |
| [15] | MAHAJAN A, SCHRODER L, REKHTMAN A, et al. Tremor-dominant cervical dystonia: A cerebellar syndrome[J]. Cerebellum, 2021, 20(2):300-305. |
| [16] | KREISLER A, SIMONIN C, DEGARDIN A, et al. Anatomy-guided injections of botulinum neurotoxin in neck muscles: How accurate is needle placement?[J]. Eur J Neurol, 2020, 27(11):2142-2146. |
| [17] | NIJMEIJER S W, KOELMAN J H, STANDAAR T S, et al. Cervical dystonia: Improved treatment response to botulinum toxin after referral to a tertiary centre and the use of polymyography[J]. Parkinsonism Relat Disord, 2013, 19(5):533-538. |
| [18] | KO Y D, YUN S I, RYOO D, et al. Accuracy of ultrasound-guided and non-guided botulinum toxin injection into neck muscles involved in cervical dystonia: A cadaveric study[J]. Ann Rehabil Med, 2020, 44(5):370-377. |
| [19] | TY?LEROWICZ M, DULSKI J, GAWRYLUK J, et al. Does ultrasound guidance improve the effectiveness of neurotoxin injections in patients with cervical dystonia? (a prospective, partially-blinded, clinical study)[J/OL]. Toxins, 2022,14(10):674[2025-12-31]. . |
| [20] | KREISLER A, MORTAIN L, WATEL K, et al. Doses of botulinum toxin in cervical dystonia: Does ultrasound guidance change injection practices?[J/OL]. Toxins, 2024, 16(10):439[2025-12-31]. . |
| [21] | LEE I H, YOON Y C, SUNG D H, et al. Initial experience with imaging-guided intramuscular botulinum toxin injection in patients with idiopathic cervical dystonia[J]. AJR Am J Roentgenol, 2009, 192(4):996-1001. |
| [22] | SUNG D H, CHOI J Y, KIM D H, et al. Localization of dystonic muscles with 18F-FDG PET/CT in idiopathic cervical dystonia[J]. J Nucl Med, 2007, 48(11):1790-1795. |
| [23] | KWON H R, LEE H, SUNG D H, et al. Therapeutic efficacy and prediction of 18F-FDG PET/CT-assisted botulinum toxin therapy in patients with idiopathic cervical dystonia[J/OL]. Clin Nucl Med, 2022, 47(12):e725-e730. . |
| [24] | MATAK I, LACKOVI? Z. Botulinum toxin A, brain and pain[J]. Prog Neurobiol, 2014, 119-120:39-59. |
| [25] | WEISE D, WEISE C M, NAUMANN M. Central effects of botulinum neurotoxin-evidence from human studies[J/OL]. Toxins, 2019, 11(1):21[2025-12-31]. . |
| [26] | GRIMM K, PRILOP L, SCH?N G, et al. Cerebellar modulation of sensorimotor associative plasticity is impaired in cervical dystonia[J]. Mov Disord, 2023, 38(11):2084-2093. |
| [27] | KOJOVIC M, CARONNI A, BOLOGNA M, et al. Botulinum toxin injections reduce associative plasticity in patients with primary dystonia[J]. Mov Disord, 2011, 26(7):1282-1289. |
| [28] | HOK P, VEVERKA T, HLU?TíK P, et al. The central effects of botulinum toxin in dystonia and spasticity[J/OL]. Toxins, 2021, 13(2):155[2025-12-31]. . |
| [29] | HAST M A, KONG A M, DESAI S, et al. Patient characteristics and real-world use of botulinum toxins for the treatment of cervical dystonia, blepharospasm, and hemifacial spasm[J/OL]. Toxins, 2024, 16(8):362[2025-12-31]. . |
| [30] | HSIUNG G Y, DAS S K, RANAWAYA R, et al. Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period[J]. Mov Disord, 2002, 17(6):1288-1293. |
| [31] | DUARTE G S, RODRIGUES F B, FERREIRA J J, et al. Adverse events with botulinum toxin treatment in cervical dystonia: How much should we blame placebo?[J]. Park Relat Disord, 2018, 56:16-19. |
| [32] | RATO M L, DUARTE G S, MESTRE T, et al. Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions[J/OL]. Lancet Neurol, 2018, 17(10):842[2025-12-31]. . |
| [33] | LEAL RATO M, DUARTE G S, FERREIRA A N, et al. Nocebo response in Parkinson's disease: A systematic review and meta-analysis[J]. Parkinsonism Relat Disord, 2019, 65:13-19. |
| [34] | SY M A C, FERNANDEZ H H. Dystonia and leveraging oral pharmacotherapy[J]. J Neural Transm (Vienna), 2021, 128(4):521-529. |
| [35] | ANDRE L, GALLINI A, MONTASTRUC F, et al. Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old: A systematic review[J]. Eur J Clin Pharmacol, 2019, 75(12):1631-1644. |
| [36] | RODRIGUES F B, DUARTE G S, CASTEL?O M, et al. Botulinum toxin type A versus anticholinergics for cervical dystonia[J/OL]. Cochrane Database Syst Rev, 2021, 4(4):CD004312[2025-12-31]. . |
| [37] | BERMAN B D, POLLARD R T, SHELTON E, et al. GABAA receptor availability changes underlie symptoms in isolated cervical dystonia[J/OL]. Front Neurol, 2018, 9:188[2025-12-31]. . |
| [38] | PIRIO RICHARDSON S, WEGELE A R, SKIPPER B, et al. Dystonia treatment: Patterns of medication use in an international cohort[J]. Neurology, 2017, 88(6):543-550. |
| [39] | JINNAH H A. Medical and surgical treatments for dystonia[J]. Neurol Clin, 2020, 38(2):325-348. |
| [40] | ABU-HADID O, JIMENEZ-SHAHED J. An overview of the pharmacotherapeutics for dystonia: Advances over the past decade[J]. Expert Opin Pharmacother, 2022, 23(17):1927-1940. |
| [41] | HULL M, ANUPINDI V R, DEKOVEN M, et al. Botulinum toxin utilization, treatment patterns, and healthcare costs among patients with spasticity or cervical dystonia in the US[J]. Adv Ther, 2023, 40(9):3986-4003. |
| [42] | LIZARRAGA K J, AL-SHORAFAT D, FOX S. Update on current and emerging therapies for dystonia[J]. Neurodegener Dis Manag, 2019, 9(3):135-147. |
| [43] | LEE W W, JEON B, KIM R. Expanding the spectrum of dopa-responsive dystonia (DRD) and proposal for new definition: DRD, DRD-plus, and DRD look-alike[J/OL]. J Korean Med Sci, 2018, 33(28):e184[2025-12-31]. . |
| [44] | RIBOT B, AUPY J, VIDAILHET M, et al. Dystonia and dopamine: From phenomenology to pathophysiology[J/OL]. Prog Neurobiol, 2019, 182:101678[2025-12-31]. . |
| [45] | MATSUMOTO S S, KOIZUMI H, SHIMAZU H, et al. Therapeutic effects of dual dopaminergic modulation with L-DOPA and chlorpromazine in patients with idiopathic cervical dystonia[J/OL]. Neurol Clin Pract, 2024, 14(2):e200254[2025-12-31]. . |
| [46] | LI X H, LIN S C, HU Y F, et al. Efficacy of carbamazepine combined with botulinum toxin a in the treatment of blepharospasm and hemifacial spasm[J]. Eye Sci, 2012, 27(4):178-181. |
| [47] | MORO E, GROSS R E, KRAUSS J K. What's new in surgical treatment for dystonia?[J]. Mov Disord, 2013, 28(7):1013-1020. |
| [48] | KRAUSS J K. Surgical treatment of dystonia[J]. Euro J Neurology, 2010, 17(s1):97-101. |
| [49] | BRüGGEMANN N, KüHN A, SCHNEIDER S A, et al. Short- and long-term outcome of chronic pallidal neurostimulation in monogenic isolated dystonia[J]. Neurology, 2015, 84(9):895-903. |
| [50] | REESE R, VOLKMANN J. Deep brain stimulation for the dystonias: Evidence, knowledge gaps, and practical considerations[J]. Mov Disord Clin Pract, 2017, 4(4):486-494. |
| [51] | FOX M D, ALTERMAN R L. Brain stimulation for torsion dystonia[J]. JAMA Neurol, 2015, 72(6):713-719. |
| [52] | MACEROLLO A, SAJIN V, BONELLO M, et al. Deep brain stimulation in dystonia: State of art and future directions[J/OL]. J Neurosci Meth, 2020, 340:108750[2025-12-31]. . |
| [53] | HALLETT M, AYBEK S, DWORETZKY B A, et al. Functional neurological disorder: New subtypes and shared mechanisms[J]. Lancet Neurol, 2022, 21(6):537-550. |
| [54] | STEPHEN C D, PEREZ D L, CHIBNIK L B, et al. Functional dystonia: A case-control study and risk prediction algorithm[J]. Ann Clin Transl Neurol, 2021, 8(4):732-748. |
| [55] | LAGRAND T, TUITERT I, KLAMER M, et al. Functional or not functional; that's the question: Can we predict the diagnosis functional movement disorder based on associated features?[J]. Euro J Neurology, 2021, 28(1):33-39. |
| [56] | VOLKMANN J, MUELLER J, DEUSCHL G, et al. Pallidal neurostimulation in patients with medication-refractory cervical dystonia: A randomised, sham-controlled trial[J]. Lancet Neurol, 2014, 13(9):875-884. |
| [57] | TSUBOI T, WONG J K, ALMEIDA L, et al. A pooled meta-analysis of GPi and STN deep brain stimulation outcomes for cervical dystonia[J]. J Neurol, 2020, 267(5):1278-1290. |
| [58] | HOCK A N, JENSEN S R, SVAERKE K W, et al. A randomised double-blind controlled study of Deep Brain Stimulation for dystonia in STN or GPi - A long term follow-up after up to 15 years[J]. Parkinsonism Relat Disord, 2022, 96:74-79. |
| [59] | TIAN W, ZHU G, FAN S, et al. STN and GPi-deep brain stimulation for primary cervical dystonia[J]. J Coll Physicians Surg Pak, 2025, 35(2):234-237. |
| [60] | DE SOUZA J C C, FALCONE A C M, BARBOSA R M G, et al. Botulinum toxin and deep brain stimulation in dystonia[J/OL]. Toxins, 2024, 16(6):282[2025-12-31]. . |
| [61] | MARTINEZ-NUNEZ A E, SIDIROPOULOS C, WALL J, et al. Adjuvant medical therapy in cervical dystonia after deep brain stimulation: A retrospective analysis[J/OL]. Front Neurol, 2022, 13:927573[2025-12-31]. . |
| [62] | KRAUSE P, V?LZMANN S, EWERT S, et al. Long-term effects of bilateral pallidal deep brain stimulation in dystonia: A follow-up between 8 and 16 years[J]. J Neurol, 2020, 267(6):1622-1631. |
| [63] | EGGINK H, SZLUFIK S, COENEN M A, et al. Non-motor effects of deep brain stimulation in dystonia: A systematic review[J]. Park Relat Disord, 2018, 55:26-44. |
| [64] | KHANOM A A, FRANCESCHINI P R, LANE S, et al. Bilateral globus pallidus internus (GPi) deep brain stimulation for cervical dystonia: Effects on motor and non-motor symptoms within 5 years follow[J/OL]. J Neurol Sci, 2023, 452:120752[2025-12-31]. . |
| [65] | MEONI S, ZUROWSKI M, LOZANO A M, et al. Long-term neuropsychiatric outcomes after pallidal stimulation in primary and secondary dystonia[J]. Neurology, 2015, 85(5):433-440. |
| [66] | JAHANSHAHI M, CZERNECKI V, ZUROWSKI A M. Neuropsychological, neuropsychiatric, and quality of life issues in DBS for dystonia[J]. Mov Disord, 2011, 26(S1):S63-S78. |
| [67] | FAN H, ZHENG Z, YIN Z, et al. Deep brain stimulation treating dystonia: A systematic review of targets, body distributions and etiology classifications[J/OL]. Front Hum Neurosci, 2021, 15:757579[2025-12-31]. . |
| [68] | LIN S, SHU Y, ZHANG C, et al. Globus pallidus internus versus subthalamic nucleus deep brain stimulation for isolated dystonia: A 3-year follow-up[J]. Euro J Neurology, 2023, 30(9):2629-2640. |
| [69] | YOUSEF O, ABBAS A, ABDELMESEH M, et al. Subthalamic nucleus versus globus pallidus internus deep brain stimulation in the treatment of dystonia: A systematic review and meta-analysis of safety and efficacy[J/OL]. J Clin Neurosci, 2025, 132:110958[2025-12-31]. . |
| [70] | KALOGIROU E, VOULGARIS S, ALEXIOU G A. Efficacy and safety of multiple-target deep brain stimulation in non-Parkinsonian movement disorders: A systematic review[J/OL]. Neurosurg Rev, 2025, 48(1):512[2025-12-31]. . |
| [71] | KANTZANOU M, KORFIAS S, PANOURIAS I, et al. Deep brain stimulation-related surgical site infections: A systematic review and meta-analysis[J]. Neuromodulation, 2021, 24(2):197-211. |
| [72] | WANG J, LI J, HAN L, et al. Selective peripheral denervation for the treatment of spasmodic torticollis: Long-term follow-up results from 648 patients[J]. Acta Neurochir, 2015, 157(3):427-433. |
| [73] | QIU Y, XUE T, BAI Y, et al. Comparison of different surgical strategies for cervical dystonia: Evidence from Bayesian network analysis[J/OL]. Eur J Neurol, 2025, 32(1):e16527[2025-12-31]. . |
| [74] | BERGENHEIM A T, NORDH E, LARSSON E, et al. Selective peripheral denervation for cervical dystonia: Long-term follow-up[J]. J Neurol Neurosurg Psychiatry, 2015, 86(12):1307-1313. |
| [75] | ALAFACI C, GRANATA F, CUTUGNO M, et al. Presurgical evaluation of hemifacial spasm and spasmodic torticollis caused by a neurovascular conflict from AICA with 3T MRI integrated by 3D drive and 3D TOF image fusion: A case report and review of the literature[J/OL]. Surg Neurol Int, 2014, 5:108[2025-12-31]. . |
| [76] | PU B, LI C, LI J, et al. Improvement of quality of life and mental health in patients with spasmodic torticollis after microvascular decompression[J]. Clin Neurol Neurosurg, 2019, 180:57-60. |
| [77] | KRACK P, MARTINEZ-FERNANDEZ R, DEL ALAMO M, et al. Current applications and limitations of surgical treatments for movement disorders[J]. Mov Disord, 2017, 32(1):36-52. |
| [78] | 范顺, 李华南, 张海宁, 等. 王金贵教授痉挛性斜颈中医辨证思路及用药经验浅谈[J]. 天津中医药, 2022, 39(2):211-214. |
| [79] | 曾访溪, 庄礼兴. 庄礼兴调神针法治疗痉挛性斜颈经验[J]. 广州中医药大学学报, 2018, 35(2):345-347. |
| [80] | 李进阳, 李华南, 商蔚然, 等. 中医药治疗痉挛性斜颈的文献计量学分析[J]. 中医临床研究, 2025, 17(15):91-95. |
| [81] | 李辉. 孙氏腹针疗法治疗痉挛性斜颈[J]. 中国医药指南, 2014, 12(26):279-280. |
| [82] | 刘文文, 陈楚云, 李丽霞. 李丽霞治疗痉挛性斜颈验案[J]. 中华中医药杂志, 2018, 33(12):5456-5458. |
| [83] | 尹红梅. 头针结合经筋刺法治疗痉挛性斜颈一例[J]. 河南中医, 2012, 32(5):647. |
| [84] | 罗丽娥, 王月高, 林海蓉. 足部按摩加蜂针疗法治疗两例痉挛性斜颈[J]. 双足与保健, 2000, (2):18-19. |
| [85] | 岳运青, 岳进, 卢敏. 朱琏针法配合艾灸治疗痉挛性斜颈25例临床观察[J]. 云南中医中药杂志, 2016, 37(1):47-48. |
| [86] | 徐继光, 徐华. 埋线治愈痉挛性斜颈1例[J]. 上海针灸杂志, 2000, (6):44-45. |
| [87] | 海兴华, 李华南, 张玮, 等. 王金贵教授运用推拿结合中药治疗痉挛性斜颈验案举隅[J]. 四川中医, 2016, 34(10):93-95. |
| [88] | 苏佳琦, 杜旭, 殷克敬. 殷克敬教授论治痉挛性斜颈临证经验撷要[J]. 针灸临床杂志, 2023, 39(7):85-88. |
| [89] | 李晓宇, 孙海榉, 方剑乔. 方剑乔教授辨治原发性颈部肌张力障碍的辨证思路[J]. 中国针灸, 2018, 38(9):985-988. |
| [90] | KASSAYE S G, DE HERTOGH W, CROSIERS D, et al. The effectiveness of physiotherapy for patients with isolated cervical dystonia: An updated systematic review and meta-analysis[J/OL]. BMC Neurol, 2024, 24(1):53[2025-12-31]. . |
| [91] | HU W, RUNDLE-GONZALEZ V, KULKARNI S J, et al. A randomized study of botulinum toxin versus botulinum toxin plus physical therapy for treatment of cervical dystonia[J]. Park Relat Disord, 2019, 63:195-198. |
| [92] | CASTAGNA A, CARONNI A, CRIPPA A, et al. Sensorimotor Perceptive Rehabilitation Integrated (SPRInt) program: Exercises with augmented movement feedback associated to botulinum neurotoxin in idiopathic cervical dystonia-an observational study[J]. Neurol Sci, 2020, 41(1):131-138. |
| [93] | CASTAGNA A, SAIBENE E, RAMELLA M. How do I rehabilitate patients with cervical dystonia remotely?[J]. Mov Disord Clin Pract, 2021, 8(5):820-821. |
| [94] | WADON M E, MACIVER C, WINTER M, et al. Internet-based cognitive behavioural therapy as a feasible treatment of adult-onset, focal, isolated, idiopathic cervical dystonia[J/OL]. Clin Park Relat Disord, 2021, 5:100121[2025-12-31]. . |
| [95] | STAMELOU M, EDWARDS M J, HALLETT M, et al. The non-motor syndrome of primary dystonia: Clinical and pathophysiological implications[J]. Brain, 2012, 135(6):1668-1681. |
| [96] | MAIONE R, FORMICA C, QUARTARONE A, et al. The impact of non-motor symptoms on quality of life in cervical dystonia[J/OL]. J Clin Med, 2023, 12(14):4663[2025-12-31]. . |
| [97] | TIMMERS E R, VAN FAASSEN M, SMIT M, et al. Dopaminergic and serotonergic alterations in plasma in three groups of dystonia patients[J]. Park Relat Disord, 2021, 91:48-54. |
| [98] | MENCACCI N E, REYNOLDS R, RUIZ S G, et al. Dystonia genes functionally converge in specific neurons and share neurobiology with psychiatric disorders[J]. Brain, 2020, 143(9):2771-2787. |
| [99] | HUANG M, DE KONING T J, TIJSSEN M A J, et al. Cross-disease analysis of depression, Ataxia and dystonia highlights a role for synaptic plasticity and the cerebellum in the pathophysiology of these comorbid diseases[J/OL]. Biochim Biophys Acta Mol Basis Dis, 2021, 1867(1):165976[2025-12-31]. . |
| [100] | O'CONNOR S, HEVEY D, O'KEEFFE F. Illness perceptions, coping, health-related quality of life and psychological outcomes in cervical dystonia[J]. J Clin Psychol Med Settings, 2023, 30(1):129-142. |
/
| 〈 |
|
〉 |
